Clinical trial NCT00244413: Characteristics of Nondystrophic Myotonias
Official title: Nondystrophic Myotonias: Genotype-phenotype Correlation and Longitudinal Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nondystrophic Myotonias
Myotonia Congenita
Myotonic Disorders
Keywords: Myotonia
Paramyotonia Congenita
Thomsen's Disease
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
Collaborators: name: Office of Rare Diseases (ORD)
name: Rare Diseases Clinical Research Network
First posted: 2005-10-26
Enrollment: 94
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with nondystrophic myotonia

Brief summary: Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired physical activity. The purpose of this study is to better characterize the clinical features and symptoms of NDM.

Detailed description: Nondystrophic myotonias are muscle disorders caused by abnormal muscle cell membrane proteins that affect the control of muscle fiber contraction. These disorders are extremely rare, and little is known about how to best treat the various subtypes of NDM. The purpose of this study is to characterize the clinical features and symptoms of NDM as well as to pair this data with specific NDM subtypes. In turn, this may lead to the development of improved treatments. The study will also establish clinical endpoints for use in future studies.

This multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. Participants will initially attend a one-day outpatient study visit. Various baseline measurements will be collected, including demographics, medical history, and quality of life measures. Blood samples will be taken to evaluate laboratory values and genetic factors. Participants will undergo manual muscle testing (MMT), clinical myotonia assessments, and functional movement assessments. Routine nerve conduction studies and electromyography (EMG) will also be performed in order to test for the presence of myotonia in specific muscles. Annual follow-up evaluations will occur 1 and 2 years following the first study visit.

Eligibility criteria: Inclusion Criteria:

* Clinical symptoms or signs suggestive of myotonia
* Presence of myotonic potentials on electromyography (EMG)
* Persistence of symptoms and signs after discontinuation of medications that produce myotonia; such medications include fibric acid derivatives, hydroxymethylglutaryl CoA reductase inhibitors, chloroquine, and colchicine
* Absence of features suggestive of myotonic dystrophy, including ptosis, temporal wasting, mandibular weakness, cataracts occurring before age 50, and evidence of multisystem defects (cardiac conduction defects, hypogonadism)

Exclusion Criteria:

* Any other neurologic condition that might affect the assessment of the study measurements

Primary outcomes:
measure: Examine the frequency applicable events related to Nondystrophic Myotonia
timeFrame: Baseline - 3 yrs
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center, Department of Neurology
state: Kansas
city: Boston
country: United States
facility: Brigham & Women's Hospital, Department of Neurology
state: Massachusetts
city: Rochester
country: United States
facility: University of Rochester School of Medicine and Dentistry, Department of Neurology
state: New York
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
city: London
country: Canada
facility: London Health Sciences Centre, University Hospital
state: Ontario
city: London
country: United Kingdom
facility: Center for Neuromuscular Disease, Institute of Neurology and National Hospital for Neurology
Study officials:
affiliation: University of Kansas Medical Center
name: Richard Barohn, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Torbergsen T, Hodnebo A, Brautaset NJ, Loseth S, Stalberg E. A rare form of painful nondystrophic myotonia. Clin Neurophysiol. 2003 Dec;114(12):2347-54. doi: 10.1016/s1388-2457(03)00275-x.
citation: Renner DR, Ptacek LJ. Periodic paralyses and nondystrophic myotonias. Adv Neurol. 2002;88:235-52. No abstract available.
citation: Cannon SC. Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses. Kidney Int. 2000 Mar;57(3):772-9. doi: 10.1046/j.1523-1755.2000.00914.x.
citation: Cannon SC. From mutation to myotonia in sodium channel disorders. Neuromuscul Disord. 1997 Jun;7(4):241-9. doi: 10.1016/s0960-8966(97)00430-6.
citation: Moxley RT 3rd. The myotonias: their diagnosis and treatment. Compr Ther. 1996 Jan;22(1):8-21. No abstract available.
citation: Brown RH Jr. Ion channel mutations in periodic paralysis and related myotonic diseases. Ann N Y Acad Sci. 1993 Dec 20;707:305-16. doi: 10.1111/j.1749-6632.1993.tb38061.x. No abstract available.